{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "Treanor_et_al.__2011_",
  "verification_stats": {
    "total_extracted": 3,
    "verified": 0,
    "rejected": 3,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "Flublok induced serum HAI antibody responses to all three vaccine components in the majority of recipients, and the lower limit of the 95% confidence interval for response rate exceeded the US FDA criteria for licensure for all three components (lower limit of the 95% confidence interval for response rate >40% and lower limit of the 95% confidence interval for HAI titer of 1:40 or greater >70%) [2].",
      "reason": "does not support claim",
      "original_explanation": "This quote demonstrates that Flublok, a recombinant vaccine, induces strong immune responses to all three influenza components, supporting the claim that recombinant technology leads to a broad immune response."
    },
    {
      "id": "comp_2",
      "quote": "The results of the current study support the utility of insect cells for the production of well tolerated and effective vaccines for seasonal influenza.",
      "reason": "does not support claim",
      "original_explanation": "This statement affirms that recombinant technology (using insect cells) is effective for producing influenza vaccines, which supports the claim that such technology can provide broad and effective immune protection."
    },
    {
      "id": "comp_3",
      "quote": "The efficacy results also demonstrate that in adults, the minor differences in HA glycosylation seen in insect cells compared to mammalian cells and the synthesis of the HA as an uncleaved precursor do not preclude the generation of an effective immune response in adults.",
      "reason": "does not support claim",
      "original_explanation": "This quote supports the claim by indicating that recombinant technology (insect cell expression) does not hinder the ability to generate an effective and potentially broad immune response."
    }
  ],
  "model_used": "gpt-4.1"
}